# A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Source: https://onco.cc/trials/nct06326411/  
OnCo record `nct06326411` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of NST-628 run by Nested Therapeutics, Inc, now recruiting.

## Summary

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors is a phase 1 interventional study registered as NCT06326411 by Nested Therapeutics, Inc, with 230 participants planned, started 2024-04-09. Conditions recorded: Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation, Melanoma, NSCLC, Glioma, Solid Tumor, Adult and MAPK Pathway Gene Mutation. Interventions recorded: NST-628.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06326411
- Phase: 1
- Setting: A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors
- Sponsor: Nested Therapeutics, Inc
- Enrolled: 230

## Sources

- ClinicalTrials.gov NCT06326411: https://clinicaltrials.gov/study/NCT06326411

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Melanoma](https://onco.cc/cancers/melanoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [NST-628](https://onco.cc/drugs/nst-628/)
- companies: [Nested Therapeutics](https://onco.cc/companies/nested-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06326411.json